Search Videos and More
Document
Tip Sheet: Laboratory Monitoring for Patients on Oral Chemotherapy or Oral Targeted Therapies
The Breast Oncology Center developed this reference for providers on lab monitoring for patients on oral chemotherapy or oral targeted therapies in November 2025.
Course
3rd Annual Lynch Syndrome Scientific Symposium
The 3rd Annual Lynch Syndrome Scientific Symposium will be held on Monday, April 13 at Hotel Commonwealth in Boston, MA. This symposium is dedicated to researchers and clinicians focused on the study and clinical care of individuals with Lynch syndrome. We will be accepting abstracts on Lynch syndrome research and relevant case reports. The deadline to submit an abstract is February 16, 2026 at 11:59PM EST.
News
Dana-Farber Research News 01.15.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from December 16 - 31.
Symposium
Breast Cancer Breakthroughs: SABCS 2025 Highlights
Experts in Dana-Farber’s Breast Oncology Center discuss highlights in breast cancer research innovation presented at SABCS 2025 in San Antonio, Texas providing state-of-the-art information on experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease.
Symposium
Breast Cancer Breakthroughs: ESMO 2025 Highlights
Experts in Dana-Farber’s Breast Oncology Center discuss highlights in breast cancer research innovation presented at ESMO25 in Berlin, Germany, including what the data mean, how it can be used in clinic, and what’s next in the field of breast cancer research.
News
Seeing Is Believing
How Technicolor Images of Tumor Samples Are Changing Cancer Research
News
Dana-Farber Researchers Discover How Major Nuclear Protein Complexes Control Specialized Gene Regulation in Cancer and Beyond
The SWI/SNF Ig-Fold for Transcription Factor Interactions or ‘SWIFT’ domain on mSWI/SNF chromatin remodeling complexes engage proteins called transcription factors (TFs) to target specialized genes along human DNA—often cancer-promoting genes—flagging SWIFT-TF interactions as promising new therapeutic targets.
News
Dana-Farber Research News 01.01.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from December 1 - 15.
News
Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants
Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program have once again received exceptional ratings from the Center for International Blood & Marrow Transplant Research (CIBMTR), earning a +1 performance score, the highest possible designation, on their annual center-specific survival reports.
Document
Tip Sheet: Medication-Related Osteonecrosis of the Jaw
The Breast Oncology Center developed this reference for providers caring for patients with medication-related osteonecrosis of the jaw in November 2025.
News
Dana-Farber Research Supports FDA Approval of T-DXd Plus Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer
The U.S. Food and Drug Administration (FDA) has approved trastuzumab deruxtecan (T-DXd) in combination with pertuzumab for first-line treatment of metastatic HER2-positive breast cancer.
News
Dana-Farber Research News 12.15.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from November 16 - 30.